Individual predictors of increased serum mesothelin in asbestos-exposed workers

Filiberti, Rosa; Marroni, Paola; Mencoboni, Manlio; Mortara, Virginia; Caruso, Pietro; Cioè, Alex; Michelazzi, Luigi; Merlo, Domenico; Bruzzone, Andrea; Bobbio, Barbara; Del Corso, Lisette; Galli, Roberto; Taveggia, Paola; Dini, Guglielmo; Spigno, Fabio
March 2013
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
Academic Journal
The soluble mesothelin-related peptide (SMRP), a candidate marker for screening of subjects with asbestos exposure, is influenced by some individual and clinical factors. The aim of this study was to quantify the role of age, smoking, weight, presence of diseases and exposure to asbestos on serum SMRP levels in a large series of subjects exposed to asbestos, possible candidates for mesothelioma screening. One thousand seven hundred and four participants underwent clinical examination and were interviewed on medical anamnesis, occupation, smoking and weight. SMRP was measured by an ELISA assay. Overall, median SMRP was 0.4 (IQR 25-75: 0.3-0.7) nmol/l. It was higher in current smokers and in subjects with a cumulative asbestos exposure >50 ff/cc/years than in all the other subjects ( p < 0.001 and p = 0.002, respectively). SMRP was positively correlated with age (ρ = 0.11, p < 0.001) and, inversely, with BMI ( ρ = −0.15, p < 0.001). SMRP was lower in healthy subjects ( n = 1,217: median 0.4 nmol/l) than in subjects with malignant tumors ( n = 118: 0.5 nmol/l; p = 0.01), asbestos-related pleural lesions (plaques or thickenings, n = 152: 0.6 nmol/l; p < 0.001) and other benign diseases ( n = 182: 0.5 nmol/l; p = 0.04). Multivariate analysis revealed significant predictors of increased SMRP: age >57 years, current smoking, a positive anamnesis for cancer and for asbestos-related pleural lesions, and BMI < 25. Some clinical and demographic variables are associated with serum SMRP levels. The degree of these associations is low, nevertheless they should be accounted for in the interpretation of SMPR as a candidate marker predictive of mesothelioma. The potential predictive value of serum SMRP in screening/surveillance programs must be validated in prospective studies.


Related Articles

  • Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Felten, Michael; Khatab, Khaled; Knoll, Lars; Schettgen, Thomas; Müller-Berndorff, Hendrik; Kraus, Thomas // International Archives of Occupational & Environmental Health;Feb2014, Vol. 87 Issue 2, p195 

    Purpose: In patients developing malignant pleural mesothelioma (MPM) or lung cancer, using effective tumour markers is the quickest way to ensure early diagnosis and improve survival time. The aim of our study was to assess the influence of age and asbestos exposure on the blood levels of the...

  • Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Creaney, Jenette; Dick, Ian M.; Meniawy, Tarek M.; Su Lyn Leong; Leon, Justine S.; Demelker, Yvonne; Segal, Amanda; Musk, A. W. (Bill); Gary Lee, Y. C.; Skates, Steven J.; Nowak, Anna K.; Robinson, Bruce W. S. // Thorax;Oct2014, Vol. 69 Issue 10, p895 

    Background Pleural malignant mesothelioma (MM) is a deadly tumour predominantly associated with asbestos exposure. A reliable diagnostic and prognostic marker for MM will significantly enhance clinical care and is an area of intense research. Soluble mesothelin is the most studied and an...

  • Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum. Creaney, Jenette; Sneddon, Sophie; Dick, Ian M.; Dare, Hanne; Boudville, Neil; Musk, Arthur William; Skates, Steven J.; Robinson, Bruce W. S. // Disease Markers;2013, Vol. 35 Issue 2, p119 

    The MSLN gene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being investigated as biomarkers for the asbestos-related cancer malignant mesothelioma (MM). Pleural fluid biomarkers of MM can be elevated when serum levels remain normal. The aim of this study was to...

  • Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos. Bayram, Mehmet; Dongel, Isa; Akbaş, Ali; Benli, İsmail; Akkoyunlu, Muhammed; Bakan, Nur // Lung;Feb2014, Vol. 192 Issue 1, p197 

    Purpose: This study investigated the diagnostic accuracy of the serum biomarkers osteopontin and mesothelin in discriminating mesothelioma patients from those with other, benign conditions and whether levels of the biomarkers differed in subjects who had inhaled naturally occurring asbestos...

  • Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure. de Gennaro, G.; Dragonieri, S.; Longobardi, F.; Musti, M.; Stallone, G.; Trizio, L.; Tutino, M. // Analytical & Bioanalytical Chemistry;Dec2010, Vol. 398 Issue 7/8, p3043 

    Malignant pleural mesothelioma (MPM) is an aggressive tumour whose main aetiology is the long-term exposure to asbestos fibres. The diagnostic procedure of MPM is difficult and often requires invasive approaches; therefore, it is clinically important to find accurate markers for MPM by new...

  • Optimizing Metabolism. Kohlstadt, Ingrid // Townsend Letter;Oct2012, Issue 351, p36 

    The article focuses on toxin exposures and the three common but uncommonly recognized toxins relevant to some patients with chronic fatigue. It states that toxic exposures compromise health when they exceed the innate ability of the body to neutralize them. Asbestos is reportedly found in...

  • Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum. Weber, Daniel Gilbert; Johnen, Georg; Taeger, Dirk; Weber, Anne; Gross, Isabelle Mercedes; Pesch, Beate; Kraus, Thomas; Brüning, Thomas; Gube, Monika // Biomarker Insights;2010, Issue 5, p1 

    The purpose of this analysis was to evaluate if serum levels of potential tumor markers for the diagnosis of malignant mesothelioma and lung cancer are affected by confounding factors in a surveillance cohort of workers formerly exposed to asbestos. SMRP, CA125, and CYFRA21-1 concentrations were...

  • Malignant Pleural Mesothelioma Prognostic Marker: A Review of Osteopontin and Soluble Mesothelin Peptides. Alaribe, Franca N.; Maniero, Staffania; Pancaldi, Cecilia // Tropical Journal of Pharmaceutical Research;Dec2010, Vol. 9 Issue 6, p605 

    This article is a review of a series of three studies that proved the involvement of osteopontin as a prognostic marker in malignant pleural mesothelioma (MPM) cancers. The approach used involved synthesizing and analysing the three articles. The first proves the utilization of osteopontin and...

  • HOX transcription factors are potential targets and markers in malignant mesothelioma. Morgan, Richard; Simpson, Guy; Gray, Sophie; Gillett, Cheryl; Tabi, Zsuzsanna; Spicer, James; Harrington, Kevin J.; Pandha, Hardev S. // BMC Cancer;2/11/2016, Vol. 16, p1 

    Background: The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development and which are dys-regulated in some cancers. In this study we examined the expression and oncogenic function of HOX genes in mesothelioma, a cancer arising...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics